Abcuro, Inc

Abcuro, Inc. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for autoimmune diseases and cancer. Abcuro, Inc. is dedicated to pioneering treatments that modulate cytotoxic T and NK cells through the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). Their leading candidate, ABC008, is a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM). This represents a significant advancement in addressing this progressive and debilitating inflammatory skeletal muscle condition, for which there are currently no available pharmaceutical therapies. Abcuro has received FDA orphan drug designation for ABC008 in IBM.

Abcuro is also advancing ABC015, an anti-KLRG1 blocking antibody designed to reactivate inhibited cytotoxic T and NK cells within the tumor microenvironment. This novel approach holds promise for enhancing the body's natural ability to fight cancer. Abcuro, Inc. is committed to translating cutting-edge research into effective therapies that improve patient outcomes in areas of high unmet medical need. The company's mission is driven by a passion for innovation and a dedication to scientific excellence.

Abcuro, Inc. is poised to make a significant impact in the fields of autoimmune disease and oncology. The company's innovative approach to modulating the immune system offers new hope for patients seeking effective and targeted treatments. Abcuro, Inc. is committed to advancing its pipeline of novel therapies and improving the lives of patients worldwide. We invite the management of Abcuro, Inc. to create a customized and exclusive company showcase and product listing on our platform to further enhance your company's visibility and commercial reach.